

FORM 3

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>GordonMD Global Investments LP</u> (Last) (First) (Middle) 9460 WILSHIRE BLVD SUITE 420 (Street) BEVERLY CA 90212 HILLS (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 06/30/2026	3. Issuer Name and Ticker or Trading Symbol <u>Pyxis Oncology, Inc. [PYXS]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director ☒ 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person ☒ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value \$0.001 per share	10,024,909	I	See footnote ⁽¹⁾

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Common Stock Purchase Warrant	(2)	07/02/2029	Common Stock, par value \$0.001 per share	4,900,039	3.289 ⁽³⁾	D	

1. Name and Address of Reporting Person* <u>GordonMD Global Investments LP</u> (Last) (First) (Middle) 9460 WILSHIRE BLVD SUITE 420 (Street) BEVERLY CA 90212 HILLS (City) (State) (Zip)
1. Name and Address of Reporting Person* <u>GordonMD Long Biased Master Fund LP</u> (Last) (First) (Middle) 9460 WILSHIRE BLVD SUITE 420 (Street)

BEVERLY CA 90212
HILLS

(City) (State) (Zip)

1. Name and Address of Reporting Person*

GordonMD Long Biased GP LLC

(Last) (First) (Middle)

9460 WILSHIRE BLVD
SUITE 420

(Street)

BEVERLY CA 90212
HILLS

(City) (State) (Zip)

1. Name and Address of Reporting Person*

Gordon Craig D

(Last) (First) (Middle)

9460 WILSHIRE BLVD
SUITE 420

(Street)

BEVERLY CA 90212
HILLS

(City) (State) (Zip)

Explanation of Responses:

1. The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any.
2. The Common Stock Purchase Warrant is exercisable on or after the earlier of (i) the date on which the Issuer first publicly discloses clinical data from its micvotabart pelidotin (MICVO) Phase 1 monotherapy study in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) and (ii) October 1, 2026.
3. Exercise price of \$3.289, subject to adjustments as set forth in the Common Stock Purchase Warrant.

GordonMD Global
Investments LP, By:
GordonMD Global
Investments GP LLC, /s/ 07/10/2026
Craig D. Gordon,
Managing Member

GordonMD Long Biased
Master Fund LP, By:
GordonMD Long Biased
GP LLC, /s/ Craig D. 07/10/2026
Gordon, Managing
Member

GordonMD Long Biased
GP LLC, /s/ Craig D. 07/10/2026
Gordon, Managing
Member
Craig D. Gordon, /s/ Craig
D. Gordon 07/10/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.